|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8148374||BRISTOL-MYERS SQUIBB||Modulators of pharmacokinetic properties of therapeutics|| |
(5 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10039718||BRISTOL-MYERS SQUIBB||Use of solid carrier particles to improve the processability of a pharmaceutical agent|| |
(9 years from now)
Evotaz is owned by Bristol-Myers Squibb.
Evotaz contains Atazanavir Sulfate; Cobicistat.
Evotaz has a total of 2 drug patents out of which 0 drug patents have expired.
Evotaz was authorised for market use on 29 January, 2015.
Evotaz is available in tablet;oral dosage forms.
Evotaz can be used as treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase.
The generics of Evotaz are possible to be released after 06 October, 2032.
Market Authorisation Date: 29 January, 2015
Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic